At a glance
- Originator Pharmacia Corporation
- Developer AstraZeneca; Pharmacia Corporation
- Class Anti-inflammatories; Benzoic acids
- Mechanism of Action Immunomodulators; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammatory bowel diseases; Rheumatic disorders
Most Recent Events
- 17 Jan 2002 No-Development-Reported for Inflammatory bowel disease in Sweden (Unknown route)
- 17 Jan 2002 No-Development-Reported for Rheumatic disorders in Sweden (Unknown route)
- 31 Oct 1998 Phase-I clinical trials for Inflammatory bowel disease in Sweden (Unknown route)